Recruiting Urticaria Studies in Little Rock
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg l...
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks o...
A Study of Navenibart in Participants With Hereditary Angioedema
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent parti...
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared t...
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT ...
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared ...
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended...
About Urticaria Clinical Trials in Little Rock
Urticaria (hives) presents as raised, itchy welts on the skin triggered by allergens, medications, infections, or other factors. Acute urticaria resolves within six weeks, while chronic forms persist longer. Treatment includes antihistamines, corticosteroids for severe episodes, and biologics for chronic cases.
There are currently 7 urticaria clinical trials recruiting participants in Little Rock, ARKANSAS. These studies are seeking a combined 1,279 participants. Research is being sponsored by Novartis Pharmaceuticals, Astria Therapeutics, Inc., Pharvaris Netherlands B.V. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Urticaria Clinical Trials in Little Rock — FAQ
Are there urticaria clinical trials in Little Rock?
Yes, there are 7 urticaria clinical trials currently recruiting in Little Rock, ARKANSAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Little Rock?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.
Are clinical trials in Little Rock free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.
What urticaria treatments are being tested?
The 7 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for urticaria.
Data updated March 2, 2026 from ClinicalTrials.gov